Clinical trial
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or…
NCT00089089 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00089089 |
|---|---|
| Title | Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas |
| Official title | Phase I Study of Prolonged Low Dose Decitabine (5-Aza-Deoxycytidine, NSC #127716) in Patients With Biopsiable Advanced Cancers Refractory to Standard Therapy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | decitabine, pharmacological study, laboratory biomarker analysis |
| Enrollment | 42 |
| Start date | Sep 1, 2004 |
| Primary completion | Mar 1, 2008 |
| First posted | Aug 5, 2004 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: